RBC Capital analyst Luca Issi initiated coverage with a Buy rating on Meiragtx Holdings (MGTX – Research Report) yesterday and set a price target of $11.00. The company’s shares closed yesterday at $5.10.
According to TipRanks, Issi is an analyst with an average return of -22.8% and a 19.80% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Meiragtx Holdings with a $13.00 average price target.
MGTX market cap is currently $328M and has a P/E ratio of -3.98.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meiragtx Holdings (MGTX) Company Description:
MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Read More on MGTX:
- MeiraGTx Reports First Quarter 2024 Financial and Operational Results
- MeiraGTx to Participate in Upcoming Investor Conferences
- MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
- MeiraGTx expects cash to fund requirements into 1Q26
- MeiraGTx reports 2023 EPS ($1.49), consensus ($1.77)
